![Answers from the Lab artwork](https://is1-ssl.mzstatic.com/image/thumb/Podcasts123/v4/50/7c/98/507c98ef-b9df-a91a-a502-be3bb172a96a/mza_8983779036521975450.jpg/100x100bb.jpg)
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D
Answers from the Lab
English - April 23, 2024 06:00 - 5 minutes - 8.08 MBMedicine Health & Fitness Science laboratory medicine healthcare answers from the lab mayo clinic laboratories lab mayo clinic clinical dlmp morice pritt Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Lab Week and Noteworthy News: Bill Morice, M.D., Ph.D.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
(00:32)
Could you provide us with a little bit of information about yourself and your background?
(01:18)
Can you start with a brief overview of the assay?
(02:13)
Which patients should have this testing and when should it be performed?
(03:21)
Are there alternative test options available and how do those compare with the folate receptor alpha assay?
(03:57)
How are the results used in patient care?